Drug candidate bepirovirsen delivered a functional cure rate for 19% of patients in what the company sees as a breakthrough ...
The study comes months after the Advisory Committee on Immunization Practices (ACIP) voted in December 2025 to replace its ...
Across two large trials, roughly 20% of people treated with bepirovirsen had undetectable levels of the virus after stopping ...
The findings supporting bepiroversen were deemed a “historic moment” by physicians and validate a drug that has “clear ...
The sneaky virus poses serious health threats if it goes on to become a chronic disease. Clinical trial results suggest a new drug may cure 1 in 5 of those cases.
A new hepatitis B drug shows promise as a potential functional cure, allowing some patients to stop treatment while ...
Hepatitis B is sometimes referred to as the "silent killer" because people often lack symptoms – and yet the severe, long-term form of the disease can cause liver failure and death. But new evidence ...
Most people recover from the infection, but it poses great risks for those who don’t. A new drug may cure 1 in 5 of these ...
Tune Therapeutics, a leading epigenome editing company, presented new data today at the European Association for the Study of Liver (EASL) Congress in Barcelona, Spain, demonstrating the first ...
In an editorial published in the New England Journal of Medicine, University of Michigan Health hepatologist Anna S. Lok, M.D., hails newly announced results of the B-Well clinical trials as "a major ...
New research suggests a first-of-its-kind drug for hepatitis B may let some patients stop treatment without showing signs of ...
New research implies that a first-of-its-kind drug for hepatitis B could allow some patients to stop treatment without ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results